- Zenas BioPharma, an autoimmune-focused company, anticipates **top-line results around year-end** for its global Phase 3 trial of **obexelimab** in **IgG4-related disease (IgG4RD)**, with the last patient out on **November 15**.  **[1953926_tx_379730_0]** **[1953926_tx_379730_3]** 
- The company also expects results for its global Phase 2 program in **relapsing multiple sclerosis (MS) early in the fourth quarter**, and for its global Phase 2 program in **systemic lupus erythematosus (SLE) around mid-next year**.  **[1953926_tx_379730_0]** 
- Zenas BioPharma reported a **strong cash position** of approximately **$275 million as of June 30**.  **[1953926_tx_379730_0]** 
- A **$300 million Royalty Pharma deal** was announced, with **$225 million allocated to the obexelimab program and IgG4RD**, extending the company's financial runway for **more than a full year beyond the IgG4RD Phase 3 readout**.  **[1953926_tx_379730_0]** 
- The company is in **pre-commercial mode**, with Medical Affairs teams deployed in Europe and the U.S., and is preparing a Biologics License Application (BLA) for obexelimab in IgG4RD.  **[1953926_tx_379730_0]**

Zenas BioPharma (ZBIO)